Levothyroxine Substitution in Patients with Subclinical Hypothyroidism and the Risk of Myocardial Infarction and Mortality
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Subclinical hypothyroidism is associated with a number of cardiovascular risk factors, yet only limited data exist on long-term outcome of levothyroxine treatment of this condition with respect to hard end-points. The aim of this retrospective cohort study was to determine effects of levothyroxine treatment on myocardial infarction (MI), cardiovascular death and all-cause mortality, in patients with subclinical hypothyroidism. METHODS AND RESULTS: Primary care patients aged 18 years and older that underwent thyroid function tests between 2000 and 2009 were enrolled. Participants were identified by individual-level linkage of nationwide registers. Patients with subclinical hypothyroidism at baseline were included in the study. Exclusion criteria included a history of thyroid disease, related medication or medication affecting thyroid function. The total cohort comprised 628,953 patients of which 12,212 (1.9%) had subclinical hypothyroidism (mean age 55.2 [SD ± 18.8] years; 79.8% female). Within the first six months 2,483 (20.3%) patients claimed a prescription for levothyroxine. During a median follow-up of 5.0 (IQR: 5.2) years, 358 MI's and 1,566 (12.8%) deaths were observed. Out of these, 766 of the deaths were cardiovascular related. No beneficial effects were found in levothyroxine treated patients on MI (IRR 1.08 [95% CI: 0.81 to 1.44]), cardiovascular death (IRR 1.02 [95% CI: 0.83 to 1.25]) or all-cause mortality (IRR 1.03 [95% CI: 0.90 to 1.19]), except in patients under the age of 65 years (IRR 0.63 [95% CI: 0.40 to 0.99]). CONCLUSION: Levothyroxine substitution in subclinical hypothyroid patients does not indicate an association with lower mortality or decreased risk of MI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 1×
“day are often needed in overt hypothyroidism.[57] It was not possible to verify the thyroid function status of all patients due to incomplete data, but an analysis using only patients with confirmed subclinical hypothyroidism by control blood tests showed no significantly changes in the main results.”
ResultGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
Hak, A. E., Pols, H. A. P., Visser, T. J., Drexhage, H. A., Hofman, A., & Witteman, J. C. M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00004 · Cited by 1,336
Cooper, D. S., & Biondi, B. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60276-6 · Cited by 1,039 · cited 1×
“[25] Treatment of the condition remains controversial because it is still unknown whether intervention with substitution therapy is beneficial on hard endpoints such as cardiovascular disease and mortality.[26] This large register-based study was conducted to examine the hypothesis, that substitution treatment with le…”
ResultThyroid Status, Disability and Cognitive Function, and Survival in Old Age
Gussekloo, J. (2004) · JAMA · doi:10.1001/jama.292.21.2591 · Cited by 899 · cited 1×
“Previous cohort studies on subclinical hypothyroidism and hard endpoints have been conflicting with some reporting increased longevity[16, 41] and some finding no association.”
Background2013 ETA Guideline: Management of Subclinical Hypothyroidism
Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000356507 · Cited by 877
Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults
Cappola, A. R., Fried, L. P., Arnold, A. M., Danese, M. D., Kuller, L. H., Burke, G. L., Tracy, R. P., & Ladenson, P. W. (2006) · JAMA · doi:10.1001/jama.295.9.1033 · Cited by 862
Knudsen, N., Laurberg, P., Rasmussen, L. B., Bülow, I., Perrild, H., Ovesen, L., & Jørgensen, T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2225 · Cited by 753
Subclinical thyroid dysfunction as a risk factor for cardiovascular disease
Walsh, J. P., Bremner, A. P., Bulsara, M. K., O’Leary, P., Leedman, P. J., Feddema, P., & Michelangeli, V. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.21.2467 · Cited by 536
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death
Rodondi, N., Newman, A. B., Vittinghoff, E., de Rekeneire, N., Satterfield, S., Harris, T. B., & Bauer, D. C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.21.2460 · Cited by 503
L-Thyroxine Therapy in Subclinical Hypothyroidism: A Double-Blind, Placebo-Controlled Trial
COOPER, D. S., HALPERN, R., WOOD, L. C., LEVIN, A. A., & RIDGWAY, E. C. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-1-18 · Cited by 423 · cited 1×
“physical wellbeing and mitigation of general fatigue.[47, 48] The potential harmful effects of treatment (and overtreatment) with levothyroxine are wellknown and include cardiovascular and skeletal side effects.”
BackgroundGharib, H., Tuttle, R. M., Baskin, H. J., Fish, L. H., Singer, P. A., & McDermott, M. T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1231 · Cited by 394
Razvi, S., Ingoe, L., Keeka, G., Oates, C., McMillan, C., & Weaver, J. U. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1869 · Cited by 389
Faber, J., & Galløe, A. M. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1300350 · Cited by 377
Self-citationThyroid hormone replacement for subclinical hypothyroidism
Villar, H. C. C. E., Saconato, H., Valente, O., & Atallah, Á. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003419.pub2 · Cited by 329
Fox, C. S. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.587 · Cited by 303
Selmer, C., Olesen, J. B., Hansen, M. L., von Kappelgaard, L. M., Madsen, J. C., Hansen, P. R., Pedersen, O. D., Faber, J., Torp-Pedersen, C., & Gislason, G. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4184 · Cited by 288
Self-citationRazvi, S., Weaver, J. U., Butler, T. J., & Pearce, S. H. S. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.1159 · Cited by 266
Singh, S., Duggal, J., Molnar, J., Maldonado, F., Barsano, C. P., & Arora, R. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.02.027 · Cited by 243
Lazarus, J. H. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.06.002 · Cited by 230
The Natural History of Subclinical Hypothyroidism in the Elderly: The Cardiovascular Health Study
Somwaru, L. L., Rariy, C. M., Arnold, A. M., & Cappola, A. R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3047 · Cited by 210 · cited 1×
“On the other hand, some patients with subclinical hypothyroidism might progress to overt hypothyroidism, which could overestimate the risk in this study.[56] Another limitation is the definition of the treated patient group.”
BackgroundAppelhof, B. C., Fliers, E., Wekking, E. M., Schene, A. H., Huyser, J., Tijssen, J. G. P., Endert, E., van Weert, H. C. P. M., & Wiersinga, W. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2111 · Cited by 183
Tanis, B. C., Westendorp, R. G. J., & Smelt, A. H. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.739560.x · Cited by 177 · cited 2×
“[1] The condition is associated with a number of cardiovascular risk factors such as diastolic hypertension,[2, 3] weight gain,[4–6] insulin resistance,[7] hypercholesterolemia,[8] dyslipidaemia,[9] coronary heart disease[10, 11] and ischemic heart disease.”
BackgroundResultEffects of amiodarone therapy on thyroid function
Cohen-Lehman, J., Dahl, P., Danzi, S., & Klein, I. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.225 · Cited by 157 · cited 1×
“[34, 35] Medication known to affect thyroid function, such as thyroid hormones, anti-thyroid medications, lithium, amiodarone, and glucocorticoids,[36, 37] were identified from The Danish Register of Medicinal Product Statistics.”
Background
Cited by
Subclinical Hypothyroidism: A Review
Biondi, B., Cappola, A. R., & Cooper, D. S. (2019) · JAMA · doi:10.1001/jama.2019.9052 · Cited by 604
Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2018) · Thyroid · doi:10.1089/thy.2017.0517 · Cited by 150
Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0006 · Cited by 100
Peng, C. C.-H., Huang, H.-K., Wu, B. B.-C., Chang, R. H.-E., Tu, Y.-K., & Munir, K. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa777 · Cited by 52
Ross, D. S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13410 · Cited by 42
Metadata
- Authors
- Andersen, M. N., Olsen, A.-M. S., Madsen, J. C., Faber, J., Torp-Pedersen, C., Gislason, G. H., & Selmer, C.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-12
- Volume
- 10
- Issue
- 6
- Pages
- e0129793
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2170465036
- Cited by
- 75
- References
- 27
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.